CLDI: Calidi Biotherapeutics Price/Earnings to Growth Multiple
Calidi Biotherapeutics brings together leading cell biologists to create innovative stem cell platforms. The P/E to growth history on the GURU.Markets terminal linear chart reflects valuation dynamics, where the value 0.00 denotes the current metric. Calidi Biotherapeutics implements precise methods for delivering viruses to tumors, earning deep trust from the professional oncological community and the loyalty of long-term investors.
Analytical breakdowns for Calidi Biotherapeutics (CLDI)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Calidi Biotherapeutics|CLDI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio calidibio.com|CLDI - Company Aggregate Debts|Debts to Book Capitalization Calidi Bio|CLDI - Company Long-Term Debt|Company Short-Term Debt Calidi Biotherapeutics|Interim Coverage Ratio calidibio.com
- company profitability and valuation multiples indicators:
CLDI - Net Profit|Net Profit Forecast Calidi Biotherapeutics|CLDI - P/E Multiple|Market Cap to Projected Earnings calidibio.com|CLDI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Calidi Bio|CLDI - Operating profit EBITDA|Earnings per share for the last twelve months Calidi Biotherapeutics|CLDI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months calidibio.com|CLDI - Earnings per share growth in current year|Expected net earnings per share growth next year Calidi Biotherapeutics
General company analysis:CLDI Calidi Biotherapeutics Inc.
The PEG ratio compares the current P/E multiple with earnings growth rates, where a value below one signals a fundamental undervaluation of the asset relative to its expansion. By analyzing this indicator of undervaluation relative to growth, an investor can assess the market value of Calidi Biotherapeutics (CLDI) through the prism of the uniqueness of their platform for delivering oncolytic viruses into tumors via stem cells.
Competitors of Calidi Biotherapeutics
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|PEG Multiple DCTH|Price/Earnings to Growth Multiple ymabs.com YMAB|PEG Multiple AURA (Aura Biosciences)|PEG Multiple Candel Therapeutics Inc. CADL|ARAY - Price/Earnings to Growth Ratio|SLS: Price/Earnings to Growth Ratio|ACTU: PEG Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|HURA (TuHURA Biosciences Inc.) - PEG Multiple|Growth-Adjusted P/E Ratio TARA (Protara Therapeutics Inc)|PEG Multiple FATE|Growth-Adjusted Market Cap to Net Income aadibio.com|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio CSBR|XBiotech USA - PEG Multiple|CVM: Price/Earnings to Growth Ratio|OSTX: PEG Multiple|RADX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Artiva Biotherapeutics Inc.|Price to Earnings Adjusted for Growth Rate Adlai Nortye Limited ANL|Price/Earnings to Growth Multiple VERU (Veru)|Company Value to Earnings Growth Ratio TPST|PEG Multiple XLO (Xilio Therapeutics)|Growth-Adjusted Payback Ratio RENB|Mural Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Price/Earnings to Growth Ratio|CytoMed Therapeutics Limited - Growth-Adjusted Payback Ratio|CRIS (Curis Inc.) - PEG Multiple|PEG Multiple Apollomics Corp|Price/Earnings to Growth Ratio Tharimmune, Inc. (THAR)|ADVB: Market Cap to Earnings and Growth Ratio|PEG Multiple GNPX (Genprex)|Sunshine Biopharma Inc. (SBFM) - Price to Earnings Adjusted for Growth Rate|XBIO: Price/Earnings to Growth Multiple|SLRX - PEG Multiple|PPBT (Purple Biotech) - Price/Earnings to Growth Multiple|AONC: Company Value to Earnings Growth Ratio|BGNE (BeiGene) - PEG Multiple|Checkpoint Therapeutics Inc. (CKPT) - Growth-Adjusted Market Cap to Net Income|PEG Multiple ELEV|Price/Earnings to Growth Multiple icadmed.com ICAD|Price/Earnings to Growth Ratio Ikena Oncology IKNA|Growth-Adjusted Market Cap to Net Income notablelabs.com (NTBL)|Viracta - PEG Multiple|MorphoSys Inc (MOR) - Price/Earnings to Growth Multiple|NAYA Bio (NAYA) - Price/Earnings to Growth Ratio|AAPGV (Ascentage) - Price/Earnings to Growth Ratio
